Ranked #3,740 of 8,699 institutional investors
Sector Gamma AS
Oslo, Q8
$479M
US stock portfolio at live prices · today −$7.6M (−1.56%)
Market closed. Prices as of Nov 20, 7:41 AM ET
- Value at quarter end (Q3 2026)
- $485M
- Change from Q2 2026
- +$24.0M (+5.20%)
- Positions
- 37 · 6 new, 5 sold out
- Filed
- Nov 12, 2026
Not counted in the ranking: none$54.5M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesBMY 7.46%PFE 7.29%MRK 5.35%GEHC 4.39%BMRN 3.76%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | 612,962 | $35.8M | 7.46% | Reduced −16% |
| PFE Pfizer Inc. | 1,267,334 | $34.9M | 7.29% | Added +26% |
| MRK Merck & Co., Inc. | 193,044 | $25.6M | 5.35% | Reduced −11% |
| GEHC GE HealthCare Technologies Inc. | 256,906 | $21.0M | 4.39% | Added +24% |
| BMRN BioMarin Pharmaceutical Inc. | 293,293 | $18.0M | 3.76% | Reduced −1% |
| INCY Incyte Corporation | 155,100 | $18.0M | 3.75% | Reduced −9% |
| BIIB Biogen Inc. | 66,646 | $16.5M | 3.44% | Added +23% |
| BDX Becton, Dickinson and Company | 75,630 | $16.1M | 3.36% | Reduced −19% |
| CVS CVS Health Corporation | 196,574 | $15.7M | 3.28% | Added +27% |
| ELV Elevance Health, Inc. | 40,229 | $15.7M | 3.28% | Reduced −10% |
| ABT Abbott Laboratories | 141,741 | $14.7M | 3.07% | Reduced −4% |
| DHR Danaher Corporation | 63,381 | $14.4M | 3.01% | New |
| BRKR Bruker Corporation | 217,352 | $13.5M | 2.82% | Added +43% |
| ZBH Zimmer Biomet Holdings, Inc. | 131,484 | $13.3M | 2.79% | Reduced −8% |
| BSX Boston Scientific Corporation | 308,128 | $13.2M | 2.77% | Added +154% |
| REGN Regeneron Pharmaceuticals, Inc. | 14,184 | $13.1M | 2.73% | Reduced −10% |
| BIO Bio-Rad Laboratories, Inc. | 33,350 | $12.3M | 2.56% | Unchanged |
| LH Labcorp Holdings Inc. | 31,019 | $11.4M | 2.39% | Added +19% |
| CAH Cardinal Health, Inc. | 40,301 | $11.0M | 2.29% | Reduced −1% |
| IQV IQVIA Holdings Inc. | 42,283 | $10.6M | 2.21% | Reduced −46% |
| CNC Centene Corporation | 142,405 | $9.3M | 1.95% | Reduced −12% |
| AVTR Avantor, Inc. | 606,088 | $9.2M | 1.91% | Reduced −33% |
| IONS Ionis Pharmaceuticals, Inc. | 330,037 | $9.0M | 1.88% | Added +74% |
| UNH UnitedHealth Group Incorporated | 20,000 | $6.6M | 1.38% | New |
| PTCT PTC Therapeutics, Inc. | 112,000 | $6.5M | 1.36% | Added +12% |
| EW Edwards Lifesciences Corporation | 60,402 | $6.3M | 1.31% | Unchanged |
| HCA HCA Healthcare, Inc. | 10,000 | $4.6M | 0.96% | New |
| TNDM Tandem Diabetes Care, Inc. | 267,091 | $4.5M | 0.94% | Unchanged |
| TVTX Travere Therapeutics, Inc. | 68,000 | $3.3M | 0.69% | Reduced −15% |
| KURA Kura Oncology, Inc. | 433,012 | $3.2M | 0.66% | Unchanged |
| IOVA Iovance Biotherapeutics, Inc. | 388,466 | $2.8M | 0.59% | Reduced −60% |
| VRDN Viridian Therapeutics, Inc. | 84,867 | $2.7M | 0.56% | New |
| MDGL Madrigal Pharmaceuticals, Inc. | 6,500 | $2.6M | 0.54% | New |
| DNLI Denali Therapeutics Inc. | 137,718 | $2.5M | 0.52% | New |
| CYTK Cytokinetics, Incorporated | 45,000 | $2.3M | 0.48% | Unchanged |
| SNDX Syndax Pharmaceuticals, Inc. | 241,739 | $2.2M | 0.46% | Unchanged |
| ARDX Ardelyx, Inc. | 686,844 | $2.1M | 0.44% | Unchanged |